Tavalisse
(fostamatinib disodium hexahydrate)

NOTICE

This policy contains information which is clinical in nature. The policy is not medical advice. The information in this policy is used by Wellmark to make determinations whether medical treatment is covered under the terms of a Wellmark member's health benefit plan. Physicians and other health care providers are responsible for medical advice and treatment. If you have specific health care needs, you should consult an appropriate health care professional. If you would like to request an accessible version of this document, please contact customer service at 800-524-9242.

BENEFIT APPLICATION

Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions may apply. Benefits may vary based on contract, and individual member benefits must be verified. Wellmark determines medical necessity only if the benefit exists and no contract exclusions are applicable. This medical policy may not apply to FEP. Benefits are determined by the Federal Employee Program.

DESCRIPTION

The indications below including FDA-approved indications and compendial uses are considered covered benefits provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications
Treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

POLICY

Documentation
Submission of the following information is necessary to initiate the prior authorization review: pretreatment and current platelet counts

Criteria for Initial Approval

A. Chronic immune thrombocytopenia (ITP)
   Authorization of 12 weeks may be granted to members with chronic ITP who meet all of the following criteria:
   1. Inadequate response or intolerance to prior therapy such as corticosteroids, immunoglobulins, splenectomy, or thrombopoietin receptor agonists.
   2. Untransfused platelet count at any point prior to the initiation of the requested medication is less than 30x10^9/L OR 30x10^9/L to 50x10^9/L with symptomatic bleeding (e.g., significant mucous membrane bleeding, gastrointestinal bleeding or trauma) or risk factors for bleeding (see Appendix).
Continuation of Therapy

A. Chronic immune thrombocytopenia (ITP)

1. Authorization of 3 months may be granted to members with current platelet count less than 50x10^9/L for whom the platelet count is not sufficient to prevent clinically important bleeding and who have not received a maximal Tavalisse dose for at least 8 weeks.

2. Authorization of 12 months may be granted to members with current platelet count less than 50x10^9/L for whom the current platelet count is sufficient to prevent clinically important bleeding.

3. Authorization of 12 months may be granted to members with current platelet count of 50x10^9/L to 200x10^9/L.

4. Authorization of 12 months may be granted to members with current platelet count greater than 200x10^9/L to less than or equal to 400x10^9/L for whom Tavalisse dosing will be adjusted to achieve a platelet count sufficient to avoid clinically important bleeding.

Exclusions

Coverage will not be provided for members with the following exclusion: concomitant use of Tavalisse with thrombopoietin receptor agonists (e.g., Promacta, Nplate, Doptelet, Mulpleta)

Appendix

Examples of risk factors for bleeding (not all inclusive)

- Undergoing a medical or dental procedure where blood loss is anticipated
- Comorbidity (e.g., peptic ulcer disease, hypertension)
- Mandated anticoagulation therapy
- Profession (e.g., construction worker) or lifestyle (e.g., plays contact sports) that predisposes patient to trauma

Dosing and Administration

Approvals may be subject to age and dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Quantity Limit

- 2 tablets/day

PROCEDURES AND BILLING CODES

To report provider services, use appropriate CPT* codes, Alpha Numeric (HCPCS level 2) codes, Revenue codes, and/or ICD diagnostic codes.

- Not applicable

REFERENCES

POLICY HISTORY

Policy #: 05.02.47
Reviewed: October 2021
Revised: November 2020
Current Effective Date: January 20, 2021